Abdel-Salam FS, Elkheshen SA, Mahmoud AA, Basalious EB, Amer MS, Mostafa AA, Elkasabgy NA (2020) In-situ forming chitosan implant-loaded with raloxifene hydrochloride and bioactive glass nanoparticles for treatment of bone injuries: formulation and biological evaluation in animal model. Int J Pharm. https://doi.org/10.1016/j.ijpharm.2020.119213

Article  PubMed  Google Scholar 

Aditya N, Ravi PR, Avula USR, Vats R (2014) Poly (caprolactone) nanocapsules for oral delivery of raloxifene: process optimization by hybrid design approach, in vitro and in vivo evaluation. J Microencapsul. https://doi.org/10.3109/02652048.2014.885603

Article  PubMed  Google Scholar 

Ağardan NBM, Değim Z, Yılmaz Ş, Altıntaş L, Topal T (2016a) The effectiveness of raloxifene-loaded liposomes and cochleates in breast cancer therapy. AAPS PharmSciTech 17(4):968–977. https://doi.org/10.1208/s12249-015-0429-3

Article  CAS  PubMed  Google Scholar 

Ağardan NBM, Değim Z, Yılmaz Ş, Altıntaş L, Topal T (2016b) The effectiveness of raloxifene-loaded liposomes and cochleates in breast cancer therapy. AAPS PharmSciTech. https://doi.org/10.1208/s12249-015-0429-3

Article  PubMed  Google Scholar 

Ahmed OAA, Badr-Eldin SM (2018) In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance. Int J Nanomed. https://doi.org/10.2147/IJN.S181587

Article  Google Scholar 

Almeter PJ, Isaacs, JT, Hunter AN, Henderson BS, Platt T, Mitchell BJ, Do D, Brainard AB, Brown JE, Stone RM, Nguyen BH, Warren MF, Bhaktawara SA, Bossle MN, Long LM, Zapata SP, Larkin CR, Lyman TA, Larkin SA, … Lodder RA (2022) FDA approaches in monitoring drug quality, forces impacting the drug quality, and recent alternative strategies to assess quality in the US drug supply. J Pharm Innov 17(2);269. https://doi.org/10.1007/S12247-022-09659-5

Azevedo A, Coelho MP, Pinho JO, Soares PIP, Reis CP, Borges JP, Gaspar MM (2024) An alternative hybrid lipid nanosystem combining cytotoxic and magnetic properties as a tool to potentiate antitumor effect of 5-fluorouracil. Life Sci 344. https://doi.org/10.1016/J.LFS.2024.122558

Basavaiah K, Anil Kumar UR, Tharpa K, Vinay KB (2008) Validated spectrophotometric methods for the determination of raloxifene hydrochloride in pharmaceuticals. J Chil Chem Soc 53(3):1635–1639. https://doi.org/10.4067/S0717-97072008000300020

Article  CAS  Google Scholar 

Bikiaris D, Karavelidis V, Karavas E (2009) Novel biodegradable polyesters. synthesis and application as drug carriers for the preparation of raloxifene HCl loaded nanoparticles. Molecules. https://doi.org/10.3390/molecules14072410

Bonkhoff H (2018) Estrogen receptor signaling in prostate cancer: implications for carcinogenesis and tumor progression. Prostate 78(1):2–10. https://doi.org/10.1002/PROS.23446

Article  CAS  PubMed  Google Scholar 

Bulun SE (2013) Uterine fibroids. N Engl J Med 369(14):1344–1355. https://doi.org/10.1056/NEJMra1209993

Article  CAS  PubMed  Google Scholar 

Chauhan D, Yadav PK, Sultana N, Agarwal A, Dadge S, Singh N, Maity D, Chourasia MK, Gayen JR (2023) Simultaneous estimation of raloxifene and cladrin by HPLC: application to metabolic stability studies in different species. Bioanalysis 15(11):601–620. https://doi.org/10.4155/BIO-2023-0046

Article  CAS  PubMed  Google Scholar 

Chen S, Dai X, Gao Y, Shen F, Ding J, Chen Q (2017) The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer. Sci Rep 7(1);1–7. https://doi.org/10.1038/s41598-017-17265-6

Cheng Z, Li H, Chen C, Lv X, Zuo EG, Xie X, Li Z, Liu P, Li H, Chen C (2023) Application of serum SERS technology based on thermally annealed silver nanoparticle composite substrate in breast cancer. Photodiagn Photodyn Ther 41:103284. https://doi.org/10.1016/J.PDPDT.2023.103284

Article  CAS  Google Scholar 

CN102000078A - Compound raloxifene hydrochloride tablets and preparation method thereof - Google Patents. (n.d.). Retrieved September 9, 2024, from https://patents.google.com/patent/CN102000078A/en

CN104031022A - Key intermediate of raloxifene hydrochloride and preparation method for intermediate product thereof - Google Patents. (n.d.). Retrieved September 9, 2024, from https://patents.google.com/patent/CN104031022A/en

CN105476968A - Raloxifene hydrochloride orally disintegrating tablet and preparation method thereof - Google Patents. (n.d.). Retrieved September 9, 2024, from https://patents.google.com/patent/CN105476968A/en

CN109925314A - 一A raloxifene hydrochloride phospholipid complex solid dispersion and preparation thereof- Google Patents. (n.d.). Retrieved September 9, 2024, from https://patents.google.com/patent/CN109925314A/zh

CN110526895A - Preparation and separation method of raloxifene dimer - Google Patents. (n.d.). Retrieved September 9, 2024, from https://patents.google.com/patent/CN110526895A/zh

CN111138409B - Preparation method of raloxifene hydrochloride and intermediate thereof - Google Patents. (n.d.). Retrieved September 9, 2024, from https://patents.google.com/patent/CN111138409B/en

Davydov AI, Belotserkovtseva LD, Chochaeva EM (2017) Uterine fibroid management: From the past to the present (Jacques Donnez and Marie-Madeleine Dolmans, 22.11.2016). Reality, perspectives, comments. In Voprosy Ginekologii, Akusherstva i Perinatologii (Vol. 16, Issue 1, pp. 7–17). https://doi.org/10.20953/1726-1678-2017-1-7-17

Dolmans MM, Donnez J, Fellah L (2019) Uterine fibroid management: today and tomorrow. J Obstet Gynaecol Res 45(7):1222–1229. https://doi.org/10.1111/jog.14002

Article  PubMed  Google Scholar 

Donnez J, Dolmans MM (2016) Uterine fibroid management: from the present to the future. Hum Reprod Update 22(6):665–686. https://doi.org/10.1093/humupd/dmw023

Article  PubMed  PubMed Central  Google Scholar 

Drugbank.ca (2020) 1996 Raloxifene hydrochloride, Evista®. Drugs of the Future. https://www.drugbank.ca/salts/DBSALT000272

Duvernoy CS, Yeo AA, Wong M, Cox DA, Kim HM (2010) Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial. J Women’s Health1800 (2002) 19(8);1459–1465. https://doi.org/10.1089/JWH.2009.1687

Elsheikh MA, Elnaggar YSR, Gohar EY, Abdallah OY (2012) Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal. Int J Nanomed. https://doi.org/10.2147/IJN.S33186

Article  Google Scholar 

EP2253627A1 - Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin. - Google Patents. (n.d.). Retrieved September 9, 2024, from https://patents.google.com/patent/EP2253627A1/en

Ferrari M, Alberelli M, Ambrosini A (2011) Process for controlling the growth of a raloxifene hydrochloride crystal (Patent EP 2 307 399 B1)

Fontana MC, Beckenkamp A, Buffon A, Beck RCR (2014) Controlled release of raloxifene by nanoencapsulation: effect on in vitro antiproliferative activity of human breast cancer cells. Int J Nanomed. https://doi.org/10.2147/IJN.S62857

Article  Google Scholar 

Food US, Administration D (2006) drugs@ FDA. Http://Www. Accessdata. Fda. Gov/Scripts/Cder/Drugsatfda/. https://www.fda.gov/drugs

Golmohammadzadeh S, Farhadian N, Biriaee A, Dehghani F, Khameneh B (2017) Preparation, characterization and in vitro evaluation of microemulsion of raloxifene hydrochloride. Drug Dev Ind Pharm. https://doi.org/10.1080/03639045.2017.1328430

Article  PubMed  Google Scholar 

Guha L, Kumar H (2023) Drug repurposing for spinal cord injury: progress towards therapeutic intervention for primary factors and secondary complications. Pharmaceutical Medicine 37(6):463–490. https://doi.org/10.1007/S40290-023-00499-3/METRICS

Article  PubMed  Google Scholar 

Harsha Agarwal SI (2021) Drug repurposing: advantages and key approaches. Drug Discovery from Technology Networks. https://www.technologynetworks.com/drug-discovery/articles/drug-repurposing-advantages-and-key-approaches-344261

Human Metabolome Database. (2019). Human metabolome database: showing metabocard for xanthine. Canadian Institutes of Health Research,. https://hmdb.ca/metabolites/HMDB0032987

Hurst BS (2014) Uterine fibroids. In Ultrasound Imaging in Reproductive Medicine: Advances in Infertility Work-Up, Treatment, and Art (pp. 117–131). https://doi.org/10.1007/978-1-4614-9182-8_10

Jančic Stojanovic B, Rakić T, Slavković B, Kostić N, Vemić A, Malenović A (2013) Systematical approach in evaluation of LC method for determination of raloxifene hydrochloride and its impurities employing experimental design. J Pharm Anal 3(1):45. https://doi.org/10.1016/J.JPHA.2012.09.007

Article  PubMed  Google Scholar 

Jirecek S, Lee A, Pavo I, Crans G, Eppel W, Wenzl R (2004) Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 81(1):132–136. https://doi.org/10.1016/j.fertnstert.2003.06.009

Article  CAS  PubMed  Google Scholar 

Johnson AP, Jyothi SL, Vikram PH, Pramod K, Venkatesh MP, Osmani RAM, Gangadharappa HV (2024) Bioanalytical method development and validation for the quantification of raloxifene hydrochloride from mice plasma by RP-HPLC. Microchem J 201:110541. https://doi.org/10.1016/J.MICROC.2024.110541

Article  CAS  Google Scholar 

JP2017014117A - Amorphous raloxifene hydrochloride-containing solid dispersion which contains porous material - Google Patents. (n.d.). Retrieved September 9, 2024, from https://patents.google.com/patent/JP2017014117A/en

JP2017513943A - Novel production method of amorphous raloxifene hydrochloride and novel intermediate used in the same - Google Patents. (n.d.). Retrieved September 9, 2024, from https://patents.google.com/patent/JP2017513943A/en

Kalyanaramu B, Raghubabu K (2011) A quantitative assay for raloxifene hydrochloride in bulk and pharmaceutical preparations by visible spectrophotometry. J Chem Pharm Res 3(1):122–127

CAS  Google Scholar 

Kher JD, Sorathia K (2024) Bioavailability enhancement of BCS class II raloxifene hydrochloride by inclusion complex and solid dispersion techniques. Zhongguo Ying Yong Sheng Li Xue Za Zhi = Zhongguo Yingyong Shenglixue Zazhi = Chinese J Appl Physiol 40;e20240002. https://doi.org/10.62958/J.CJAP.2024.002

KR101088709B1 - Raloxifene containing solid dispersion - Google Patents (n.d.) Retrieved August 12, 2024, from https://patents.google.com/patent/KR101088709B1/en

KR20110132116A - Solid dispersion comprising raloxifene hydrochloride, manufacturing method thereof, and oral dosage form comprising the solid dispersion - Google Patents (n.d.) Retrieved September 9, 2024, from https://patents.google.com/patent/KR20110132116A/en

KR20140064440A - Novel intermediate for preparing amorphous raloxifene hydrochloride - Google Patents (n.d.) Retrieved September 9, 2024, from https://patents.google.com/patent/KR20140064440A/en

KR20160050325A - Novel solvated crystalline of Raloxifene hydrochloride and process for preparing Raloxifene hydrochloride monohydrate - Google Patents (n.d.) Retrieved September 9, 2024, from https://patents.google.com/patent/KR20160050325A/en

Kumar Reddy KP, Prathap KMS, Sharma H, Kumar KV (2019) A simple colorimetric method for the determination of raloxifene hydrochloride in pharmaceuticals using modified Romini’s reagent. Int J Anal Chem 2019. https://doi.org/10.1155/2019/3021980

Lee JH, Kim HH, Cho YH, Koo TS, Lee GW (2018) Development and evaluation of raloxifene-hydrochloride-loaded supersaturatable SMEDDS containing an acidifier. Pharmaceutics. https://doi.org/10.3390/pharmaceutics10030078

Article  PubMed  PubMed Central  Google Scholar 

Levy BS (2008) Modern management of uterine fibroids. In Acta Obstetricia et Gynecologica Scandinavica vol. 87, Issue 8, pp. 812–823. https://doi.org/10.1080/00016340802146912

Li X, Liang J, Hu J, Ma L, Yang J, Zhang A, Jing Y, Song Y, Yang Y, Feng Z, Du Z, Wang Y, Luo T, He W, Shu X, Yang S, Li Q, Mei M, Luo S, … Peng B (2024) Screening for primary aldosteronism on and off interfering medications. Endocrine 83(1);178–187. https://doi.org/10.1007/S12020-023-03520-6/METRICS

Li Y, He X, Sun B, Hu N, Li J, You R, Tao F, Fang L, Li Y, Zhai Q (2024b) Combined exposure of beta-cypermethrin and emamectin benzoate interferes with the HPO axis through oxidative stress, causing an imbalance of hormone homeostasis in female rats. Reprod Toxicol 123:108502. https://doi.org/10.1016/J.REPROTOX.2023.108502

Article  CAS  PubMed  Google Scholar 

Lou Y, Song F, Cheng M, Hu Y, Chai Y, Hu Q, Wang Q, Zhou H, Bao M, Gu J, Zhang Y (2023) Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats. PeerJ 11:e15844. https://doi.org/10.7717/PEERJ.15844/SUPP-3